Welcome to our dedicated page for Notable Labs news (Ticker: NTBL), a resource for investors and traders seeking the latest updates and insights on Notable Labs stock.
Notable Labs (NTBL) delivers precision oncology innovations through its Predictive Precision Medicines Platform (PPMP), advancing targeted cancer therapies and diagnostic solutions. This news hub provides investors and industry professionals with essential updates on clinical developments, strategic partnerships, and regulatory progress.
Access real-time announcements about Phase 2 trial results, biomarker discoveries, and therapeutic licensing agreements. Our curated collection includes earnings reports, research collaborations, and platform validation studies - all critical for evaluating NTBL's position in clinical-stage biotechnology.
Key updates cover ex vivo testing advancements, patient stratification methodologies, and companion diagnostic developments. Bookmark this page for streamlined tracking of NTBL's progress in transforming cancer treatment through predictive medicine and optimized dosing strategies.
Notable Labs (Nasdaq: NTBL) will present data on its volasertib program for acute myeloid leukemia (AML) at the Society of Hematologic Oncology (SOHO) 2024 meeting on September 4th. The presentation will provide an overview of the upcoming Phase 2 program and additional preclinical study results.
The poster, titled 'Revival of the polo-like kinase 1 (PLK1) inhibitor volasertib in relapsed/refractory acute myeloid leukemia', will be presented during the poster session on Wednesday, September 4th at 6:15 PM CDT. Notable Labs, a clinical-stage precision oncology company, is developing new cancer therapies identified by its Predictive Medicine Platform (PMP).
The company expects to begin its Phase 2 volasertib AML program in the coming months, marking a significant step in the development of this potential treatment for AML patients.
Notable Labs (Nasdaq: NTBL) announced a significant leadership change as CEO Thomas A. Bock, MD, resigned from his position and the Board of Directors. Joseph Wagner, PhD, the company's Chief Scientific Officer, has been appointed as interim CEO. The Board has initiated a search for Dr. Bock's successor.
Under Dr. Bock's leadership, Notable Labs transformed from a private diagnostic start-up to a publicly-traded clinical-stage company focused on Predictive Medicine. The company remains committed to its plans, including the initiation of the Phase 2 clinical program for volasertib in the coming months. Dr. Bock will continue as a consultant, advising the Board and offering expertise on the company's next phase.
Notable Labs (NASDAQ: NTBL) has received FDA clearance to proceed with its Phase 2 study of volasertib for relapsed/refractory acute myeloid leukemia (R/R AML). The company plans to initiate patient enrollment in the coming months, following agreement on the dosing plan. The study will evaluate volasertib in combination with decitabine, utilizing Notable's Predictive Medicine Platform (PMP) to enhance patient outcomes.
The Phase 2 trial will begin with a dose optimization lead-in, incorporating body-surface area dosing and prophylactic antibiotic treatment. Notable expects initial data from this phase in Q4 2024, followed by selective enrollment of PMP-predicted responders. Initial efficacy results are anticipated in H1 2025. This progress marks a significant step in addressing the unmet need for R/R AML patients, particularly those who have received venetoclax-based therapies.
Notable Labs, a clinical-stage precision oncology company, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024. The CEO, Thomas Bock, will discuss the company's cancer therapies developed using the Predictive Medicine Platform. The event will take place on May 13-14, 2024, in New York City, with a webcast accessible on the Notable Labs website.